Cost comparison of ranibizumab and bevacizumab

BMJ (Online)

Volumn 343, Issue 7821, 2011, Pages

  Jackson, Timothy L ^a   Kirkpatrick, Lucy ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

DRUG COST; HEALTH CARE COST; HUMAN; LETTER; LIFE EXPECTANCY; MORTALITY; PRIORITY JOURNAL; REIMBURSEMENT; RETINA MACULA AGE RELATED DEGENERATION; UNITED KINGDOM; WET AGE RELATED MACULAR DEGENERATION; COST; ECONOMICS; EXUDATIVE MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COSTS AND COST ANALYSIS; GREAT BRITAIN; HUMANS; WET MACULAR DEGENERATION;

EID: 80052405509     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d5058     Document Type: Letter

References (7)

1. Bunce C., Wormald R. Leading causes of certification for blindness and partial sight in England and Wales. BMC Public Health 2006;6:58.
2. Lucentis historical sales; 2006-2010. IMS Health.
3. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908
4. Kmietowicz Z. Doctors warn against using Avastin for macular degeneration. BMJ 2010;340:c2483.
5. Jackson T.L., Kirkpatrick L., Tang G., Prasad S. Cost analysis comparing adjuvant epimacular brachytherapy with anti-VEGF monotherapy for the management of neovascular age-related macular degeneration. Br J Ophthalmol (submitted for publication).
6. Minassian D.C., Reidy A., Lightstone A., Desai P. Modelling the prevalence of age-related macular degeneration (2010-2020) in the UK: expected impact of anti-vascular endothelial growth factor (VEGF) therapy. Br J Ophthmol 2011; online 12 February.
7. Bandello F., Lafuma A., Berdeaux G. Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity. Invest Ophthalmol Vis Sci 2007;48:96-103. (Pubitemid 47251392)